Anti-CGRP Monoclonal Antibodies for Migraine Prevention: Comprehensive Overview and Real-World Update
Comprehensive overview reviews the efficacy, safety, and real-world effectiveness of all four anti-CGRP monoclonal antibodies for migraine prevention, comparing clinical trial and real-world data.
Quick Facts
What This Study Found
All four anti-CGRP mAbs are effective for migraine prevention with good safety profiles, and real-world data largely confirms clinical trial results with additional long-term insights.
Key Numbers
No specific efficacy percentages reported in the available abstract. The study compared performance across different anti-CGRP monoclonal antibodies in the global market.
How They Did This
Overview review synthesizing clinical trial data, systematic reviews, meta-analyses, and real-world evidence for erenumab, fremanezumab, galcanezumab, and eptinezumab.
Why This Research Matters
With four CGRP antibodies available, patients and clinicians need comprehensive comparisons to make informed treatment choices. This review provides the most complete picture available.
The Bigger Picture
CGRP-targeting drugs have transformed migraine prevention from non-specific medications (originally developed for other conditions) to precision peptide-based therapies. This review represents the maturation of this drug class, with enough data to compare options and guide individualized treatment.
What This Study Doesn't Tell Us
Overview review cannot replace systematic comparison with meta-analysis. Head-to-head trials between CGRP antibodies are limited. Real-world data has inherent selection and confounding biases.
Questions This Raises
- ?Which CGRP antibody is best for chronic vs episodic migraine?
- ?Do patients who fail one CGRP antibody benefit from switching to another?
- ?What is the long-term safety profile beyond 5 years of treatment?
Trust & Context
- Key Stat:
- 4 options compared All four anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) reviewed with clinical trial and real-world data
- Evidence Grade:
- Strong evidence: overview review of an established drug class with extensive clinical trial and real-world data.
- Study Age:
- Published in 2024. Most comprehensive review of anti-CGRP mAb evidence to date.
- Original Title:
- Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario.
- Published In:
- Hospital pharmacy, 59(2), 165-172 (2024)
- Authors:
- Zovi, Andrea, Lasala, Ruggero, Ferrara, Francesco, Langella, Roberto, Vitiello, Antonio, Sabbatucci, Michela, Musazzi, Umberto Maria
- Database ID:
- RPEP-09702
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Which CGRP antibody should I choose?
All four are effective with good safety profiles. Key differences include route (3 are self-injected, 1 is IV in clinic), frequency (monthly or quarterly), and target (receptor vs ligand). Your neurologist can help choose based on your specific migraine pattern and preferences.
Do real-world results match clinical trials?
Generally yes — real-world data confirms the benefits seen in trials, though real-world patients often have more comorbidities and higher disease burden. Some patients see even better long-term results than short-duration trials suggested.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09702APA
Zovi, Andrea; Lasala, Ruggero; Ferrara, Francesco; Langella, Roberto; Vitiello, Antonio; Sabbatucci, Michela; Musazzi, Umberto Maria. (2024). Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario.. Hospital pharmacy, 59(2), 165-172. https://doi.org/10.1177/00185787231196763
MLA
Zovi, Andrea, et al. "Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario.." Hospital pharmacy, 2024. https://doi.org/10.1177/00185787231196763
RethinkPeptides
RethinkPeptides Research Database. "Anti-CGRP mAbs for the Preventive Treatment of Migraine: An ..." RPEP-09702. Retrieved from https://rethinkpeptides.com/research/zovi-2024-anticgrp-mabs-for-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.